Tag: licensing
-
Start-Up’s Air Quality Technology to Clean City Areas
10 November 2015. A start-up company is licensing research from University of Copenhagen in Denmark to develop a technology for removing air pollution from city neighborhoods. The air cleaning technology, known as gas phase advanced oxidation, is a product of the atmospheric chemistry lab led by Matthew Johnson, who also serves as chief scientist for…
-
Compound Found to Reverse Lens Clouding in Cataracts
6 November 2015. A biochemical and medical research team discovered a steroid that when given as eye drops to mice, reverses the accumulation of protein formations in cataracts. Researchers from the labs of protein chemistry professor Jason Gestwicki at University of Michigan and ophthalmology professor Usha Andley at Washington University in St. Louis published their…
-
Biotech, Accelerator to Partner on Glaucoma Treatment
30 October 2015. A new eye-drop treatment for the underlying causes of glaucoma is being developed in a collaboration between a biotechnology enterprise spun-off from Northwestern University and a company that acquires biomedical research assets. Financial aspects of the deal between Mannin Research Inc. in Toronto, Ontario, Canada and Q BioMed Inc. in New York…
-
Gene Editing Licensed for Inherited Disease Treatments
26 October 2015. A Boston biotechnology company is licensing gene-editing technologies from a nearby start-up to design treatments for cystic fibrosis and inherited blood disorders, including sickle cell disease. Vertex Pharmaceuticals, in Boston, received rights to techniques known as CRISPR-Cas9 in a deal that could bring CRISPR Therapeutics, founded in April 2014, as much as…
-
Gates Grant Funding Whooping Cough Antibody Test
21 October 2015. A protein engineering lab at University of Texas in Austin is evaluating the potential of an engineered antibody to prevent pertussis, also known as whooping cough, among newborn infants. The study and lab are led by chemical engineering professor Jennifer Maynard, who is testing the antibody under a $400,000 grant from the…
-
Novartis Licensing Depression Therapy Technology
19 October 2015. Luc Therapeutics, a biotechnology company designing treatments for psychiatric and neurological disorders, is licensing part of its technology to the pharmaceutical company Novartis to develop treatments for depression. Dollar amounts paid under the agreement to Luc Therapeutics, in Cambridge, Massachusetts, were not disclosed. Depression is a widespread condition, which when it becomes…
-
Cancer Institute Spins-Off Company, Gains Licensing Deal
14 October 2015. Ontario Institute for Cancer Research is spinning off a new enterprise to discover therapies for blood-related cancers, and will partner with Janssen Biotech Inc. to take those therapies to market. The licensing deal between Novera Therapeutics Inc., the OICR spin-off company in Toronto, and Janssen Biotech, a division of Johnson & Johnson,…
-
Spin-Off to Provide Lower-Cost Molecular Imaging Technology
13 October 2015. A new enterprise based on research at Harvard University is offering a technology that allows ordinary microscopes to display high resolution images of single molecules. The company, Ultivue Inc., is founded by and licensing technologies from the lab of Peng Yin at Harvard’s Wyss Institute for Biologically Inspired Engineering. Yin and colleagues…
-
Harvard Spin-Off Commercializing Sepsis Treatment
9 October 2015. A new enterprise spun-off from Harvard University is developing a device for treating sepsis, a life-threatening infection often contracted in hospitals. The company, Opsonix Inc. in Boston, also raised $8 million in its first round of venture funding. Opsonix is licensing a technology for treating sepsis developed in Harvard’s Wyss Institute for…
-
Diabetes Biotech Acquires GSK Spin-Off
24 September 2015. Intarcia Therapeutics, a developer of long-acting treatments for diabetes, is purchasing Phoundry Pharmaceuticals, a discoverer of engineered peptides for metabolic and other disorders. Phoundry — a spin-off company from GlaxoSmithKline in Research Triangle Park, North Carolina — is being acquired by Intarcia for an undisclosed amount of cash and stock. Intarcia, based…